



Oral Anticoagulant Therapy

Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

*Walter Ageno, MD; Alexander S. Gallus, MBBS; Ann Wittkowsky, PharmD, FCCP;
Mark Crowther, MD; Elaine M. Hylek, MD, MPH; and Gualtiero Palareti, MD*

Table S1—[Section 1.3.1] Observed Frequency of CYP2C9 and VKORC Variants Among Various Ethnic Groups¹

CYP2C9 Genetic Alleles	CYP2C9*1	CYP2C9*2	CYP2C9*3	CYP2C9*4	CYP2C9*5
Point mutation	Arg144/Ile359	Cys144/Ile359	Arg144/Leu351	Arg144/Thr359	Arg144/Glu360
Ethnic group, %					
Whites	79-86	8-19.1	6-10	ND	ND
Indigenous Canadians	91	3	6	ND	ND
African Americans	98.5	1-3.6	0.5-1.5	ND	2.3
Asians	95-98.3	0	1.7-5	0-1.6	0
VKORC genetic haplotype sequence	¹ H CCGATCTCTG H2 CCGAGCTCTG	H7 TCGGTCCGCA H8 TAGGTCCGCA H9 TACGTTCCGG			
Ethnic group, %					
Europeans	37	58			
African	14	49			
Asian	89	10			

CYP2C9*2, *3, *4, and *5 represent genetic polymorphisms of the wild-type enzyme, CYP2C9*1. ¹H and H2 represent warfarin-sensitive haplotype. H7, H8, and H9 represent warfarin-resistant haplotype. ND = not determined. (Table adapted from Ansell et al.¹) (CYP2C9 and VKORC data from Wittkowsky² and Rieder et al.³)

Table S2—[Section 1.3.1] Effect of CYP2C9 Genotype on Warfarin Dose Requirements⁴

CYP2C9 Genotype	% Reduction in Warfarin Dose Requirement, Mean (95% CI)
*1/*1	Reference
*1/*2	19.6 (17.4-21.9)
*1/*3	33.7 (29.4-38.1)
*2/*2	36.0 (29.9-42.0)
*2/*3	56.7 (49.1-64.3)
*3/*3	78.1 (72.0-84.3)

Table S4—[Section 3.2] Maximum and Trough Plasma Concentration of Rivaroxaban in Patients Undergoing Total Hip Replacement After 5 d Rivaroxaban Dosing

Dose and Regimen	C _{max} , μg/L	C _{trough} , μg/L
5 mg od	69.3	4.5
5 mg bid	39.8	8.4
10 mg od	124.6	9.1
10 mg bid	64.9	14.6
20 mg od	222.6	22.3
20 mg bid	141.9	35.1

See Table S3 legend for expansion of abbreviations. (Data from Mueck et al.⁷)

Table S3—[Section 2.2] Steady-State Maximum and Trough Plasma Concentration of Dabigatran After Daily or bid Doses of Dabigatran Etexilate Evaluated for the Prevention of VTE After Hip or Knee Replacement (150 mg and 220 mg od) and of Systemic Embolism in Nonvalvular Atrial Fibrillation (150 mg bid)

Dose and Regimen	C _{max} , ss, ng/mL	C _{trough} , ss, ng/mL
150 mg od ^a	99	14
220 mg od ^b	183 (62-447)	37 (10-96)
150 mg bid ^b	184 (64-443)	90 (31-225)

C_{max} = maximum plasma concentration; C_{trough} = trough plasma concentration; od = once daily; ss = steady state. (Data from Eriksson et al.⁵ and van Ryn et al.⁶)

^aGeometric mean. (From Eriksson et al.⁵)

^bMedian with 5th and 95th percentiles. (From van Ryn et al.⁶)

REFERENCES

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). *Chest*. 2008;133(suppl 6):160S-198S.
2. Wittkowsky AK. Pharmacology of warfarin and related anticoagulants. In: Ansell J, Oertel L, Wittkowsky A, eds. *Managing Oral Anticoagulation Therapy: Clinical and Operational Guidelines*. Vol. 1. St. Louis, MO: Facts and Comparisons; 2003: 29:1-29:15.
3. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. *N Engl J Med*. 2005;352(22):2285-2293.
4. Mentré F, Pousset F, Comets E, et al. Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients. *Clin Pharmacol Ther*. 1998;63(1):64-78.
5. Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. *J Thromb Haemost*. 2004;2(9):1573-1580.
6. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. *Thromb Haemost*. 2010;103(6):1116-1127.
7. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. *Thromb Haemost*. 2008;100(3):453-461.